A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 [carisbamate] as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 [carisbamate] as Adjunctive Therapy in Subjects With Partial Onset Seizures Followed by an Open-Label Extension Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2012

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 19 Jun 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 06 Oct 2009 Actual patient number (566) added as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Results were presented at AES 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top